The aim of the study is to examine the feasibility of using GlucoCEST to evaluate subtle BBB dysfunction in the mouse brain, by comparing it with conventional gadolinium DCE. DCE and GlucoCEST showed no significant differences between WT and 5XFAD mice (3 months). However, the degree of the response after injection was similar for DCE and GlucoCEST for all animals except one, indicating shared contributions to the signal and supporting the potential for biodegradable d-glucose as a cheap, low-risk alternative/complement to DCE MRI. More work is required to assess GlucoCEST sensitivity to low-level BBB dysfunction, such as in Alzheimer’s disease.
This abstract and the presentation materials are available to members only; a login is required.